UB Paderborn / Katalog / Suche / in CDI

26 – 50 von 107

Sortiert nach

Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer

Cancer, 2012-08, Vol.118 (15), p.3703-3709

2012

Link zum Volltext

Verfügbarkeit prüfen

Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency

Modern pathology, 2014-10, Vol.27 (10), p.1405-1411

2014

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

Cancer, 2012-01, Vol.118 (2), p.493-499

2012

Link zum Volltext

Verfügbarkeit prüfen

Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?

Journal of clinical oncology, 2008-01, Vol.26 (1), p.9-10

Kauff, Noah D

2008

Link zum Volltext

Verfügbarkeit prüfen

Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer

Annals of surgical oncology, 2017-10, Vol.24 (11), p.3116-3123

2017

Link zum Volltext

Verfügbarkeit prüfen

Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study

Gynecologic oncology, 2020-01, Vol.156 (1), p.131-139

2020

Link zum Volltext

Verfügbarkeit prüfen

Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes

The American journal of surgical pathology, 2016-03, Vol.40 (3), p.404-409

2016

Link zum Volltext

Verfügbarkeit prüfen

Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices

International journal of gynecological cancer, 2020-10, Vol.30 (10), p.1583-1588

2020

Link zum Volltext

Verfügbarkeit prüfen

How should women with early-onset endometrial cancer be evaluated for lynch syndrome?

Journal of clinical oncology, 2007-11, Vol.25 (33), p.5143-5146

Kauff, Noah D

2007

Link zum Volltext

Verfügbarkeit prüfen

Screening for familial ovarian cancer: a ray of hope and a light to steer by

Journal of clinical oncology, 2013-01, Vol.31 (1), p.8-10

2013

Link zum Volltext

Verfügbarkeit prüfen

Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy

Cancer epidemiology, biomarkers & prevention, 2015-06, Vol.24 (6), p.913-920

2015

Link zum Volltext

Verfügbarkeit prüfen

ATR mutations in endometrial cancer: a window into the role of mismatch repair defects

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3077-3078

Kauff, Noah D

2009

Link zum Volltext

Verfügbarkeit prüfen

Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies

Current opinion in oncology, 2011-09, Vol.23 (5), p.526-530

2011

Link zum Volltext

Verfügbarkeit prüfen

Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study

Clinical gastroenterology and hepatology, 2017-09, Vol.15 (9), p.1469-1470

2017

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of primary surgical cytoreduction in patients with BRCA -associated high-grade serous ovarian carcinoma

Gynecologic oncology, 2012-08, Vol.126 (2), p.224-228

2012

Link zum Volltext

Verfügbarkeit prüfen

Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant

Journal of clinical oncology, 2016-03, Vol.34 (8), p.e61-e67

2016

Link zum Volltext

Verfügbarkeit prüfen

Rare Variants of ATM and Risk for Hodgkin’s Disease and Radiation-associated Breast Cancers

Clinical cancer research, 2002-12, Vol.8 (12), p.3813-3819

2002

Link zum Volltext

Verfügbarkeit prüfen

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status

Cancer prevention research (Philadelphia, Pa.), 2011-09, Vol.4 (9), p.1401-1408

2011

Link zum Volltext

Verfügbarkeit prüfen

Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations-Reply

JAMA oncology, 2017-03, Vol.3 (3), p.417

2017

Link zum Volltext

Verfügbarkeit prüfen

Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families

Breast cancer research and treatment, 2014-06, Vol.145 (3), p.625-634

2014

Link zum Volltext

Verfügbarkeit prüfen

Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)

JNCI cancer spectrum, 2020-02, Vol.4 (1), p.pkz075

2020

Link zum Volltext

Verfügbarkeit prüfen

Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations

Journal of clinical oncology, 2010-01, Vol.28 (2), p.189-191

2010

Link zum Volltext

Verfügbarkeit prüfen

Modeling genetic risk of breast cancer

JAMA : the journal of the American Medical Association, 2007-06, Vol.297 (23), p.2637

2007

Link zum Volltext

Verfügbarkeit prüfen

Topotecan in patients with BRCA- associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers

Gynecologic oncology, 2011-11, Vol.123 (2), p.196-199

2011

Link zum Volltext

Verfügbarkeit prüfen

Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations

Cancer, 2003-04, Vol.97 (7), p.1601-1608

2003

Link zum Volltext

Verfügbarkeit prüfen

26 – 50 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(105)
Buchkapitel
(2)

Sprache

Englisch
(107)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer

Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?

Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer

Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study

Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes

Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices

How should women with early-onset endometrial cancer be evaluated for lynch syndrome?

Screening for familial ovarian cancer: a ray of hope and a light to steer by

Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy

ATR mutations in endometrial cancer: a window into the role of mismatch repair defects

Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies

Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study

Outcomes of primary surgical cytoreduction in patients with BRCA -associated high-grade serous ovarian carcinoma

Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant

Rare Variants of ATM and Risk for Hodgkin’s Disease and Radiation-associated Breast Cancers

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status

Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations-Reply

Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families

Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199)

Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations

Modeling genetic risk of breast cancer

Topotecan in patients with BRCA- associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers

Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations

Suchergebnisse filtern